Skip to main content

Capital Genomix and Blanchette Rockefeller Neurosciences Institute to Build Microarray Facility

NEW YORK, May 30 -- Capital Genomix and the Blanchette Rockefeller Neurosciences Institute plan to establish a microarray core facility, Capital said yesterday.

 

The facility, to be housed at JohnsHopkinsUniversity's Shady Grove campus in Gaithersburg, Md., will be headed by microarray researcher Pachiappan Manickam.

 

Capital, based in Chantilly, Va., holds a microarray service license from Affymetrix. The company expects the collaboration with BRNI will expand to include its own gene expression and antibody technologies, called GeneSystem320 and ImmunoMouse, respectively.

 

BRNI is a non-profit institute focusing on translational research in the area of Alzheimer's disease.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.